CBD for atopic dermatitis: what science says about cannabidiol and eczema

Atopic dermatitis is not just dry skin: it is persistent inflammation, itching that disrupts sleep and flare-ups that affect quality of life. In this context, more and more people are looking for complementary alternatives such as CBD creams for atopic dermatitis or topical CBD for the itching of eczema.

But is cannabidiol really a promising solution or simply another trend in cosmetics? In this article we analyse what science says about CBD and atopic dermatitis, its possible anti-inflammatory and anti-itch mechanisms, the available clinical evidence and what you should bear in mind before using it.

What is atopic dermatitis and why does it appear?

Atopic dermatitis is a chronic inflammatory skin disease characterised by intense itching (pruritus), dryness, redness and recurrent flare-ups (1), which involves:

• Skin barrier dysfunction
• Immune alterations
• Changes in the microbiota (such as proliferation of Staphylococcus aureus)
• Genetic predisposition

Disruption of the skin barrier causes transepidermal water loss (the skin retains water less effectively), a lower presence of lipids such as ceramides and greater susceptibility to irritants and allergens.

CBD for atopic dermatitis: what is it and why does it generate interest?

Cannabidiol (CBD) is one of the main non-psychoactive compounds of Cannabis sativa. Unlike THC, it does not produce psychotropic effects.

It is studied in dermatology for its potential properties:

• Anti-inflammatory
• Anti-itch (against itching)
• Modulation of the immune system (2)
• Possible antimicrobial activity against skin bacteria (3)

Although clinical evidence is still limited and heterogeneous, there is biological plausibility that justifies its investigation as a complementary treatment in atopic eczema.

The skin's endocannabinoid system and its relationship with atopic dermatitis

One of the most studied mechanisms is the cutaneous endocannabinoid system (ECS).

It is made up of:

• Endocannabinoids (such as anandamide)
• Regulatory enzymes
• CB1 and CB2 receptors (4)

These receptors are found in:

• Cutaneous nerve fibres
• Keratinocytes
• Skin immune cells

Alterations of the ECS have been linked to inflammatory diseases such as atopic dermatitis (5), suggesting that modulating this system could influence inflammation, itching and barrier function.

How CBD may act in atopic dermatitis

CBD as a skin anti-inflammatory: how it modulates inflammation

CBD has low direct affinity for CB1 and CB2, but it can modulate key inflammatory pathways (6):

• Inhibition of NF-κB, a central factor in inflammation (7)
• Reduction of pro-inflammatory cytokines (messengers that amplify inflammation) such as IL-6 and IL-17
• Increase in IL-10 (anti-inflammatory)
• Influence on arachidonic acid metabolism (2)

This supports the potential of CBD as an anti-inflammatory in atopic dermatitis.

Topical CBD for itching (pruritus) in eczema

Itching is the most disabling symptom of atopic dermatitis.

CBD may modulate TRP receptors (skin sensors that transmit itching and pain) involved in the transmission of itching and pain (8), which explains its possible use as topical CBD for itching in atopic dermatitis.

CBD and the skin barrier: can it improve the protective function?

Dysfunction of the skin barrier is a cornerstone of atopic eczema.

CBD may activate pathways related to PPAR-α (a pathway that regulates the skin barrier and lipids) (9), promoting:

• Keratinocyte differentiation
• Synthesis of skin lipids (such as ceramides)
• Improved barrier function

For this reason, the relationship between CBD, ceramides and atopic eczema is being investigated.

CBD and Staphylococcus aureus: antimicrobial activity on the skin

CBD has shown antimicrobial activity in vitro against Staphylococcus aureus (3), a bacterium frequently involved in atopic dermatitis flare-ups.

Although these data are preliminary, they support the hypothesis that CBD could indirectly influence the skin microbiota.

Clinical evidence for CBD in atopic dermatitis in humans

Oral CBD for atopic dermatitis

Currently there are no robust clinical trials demonstrating the efficacy of oral CBD in human atopic dermatitis.

A study with hemp seed oil showed improvement in dryness and itching, but it cannot be attributed directly to CBD (10).

CBD cream for eczema: topical studies

Some studies with topical formulations containing CBD observed improvement in pruritus and lesions (11).

However:

• Many studies are small
• Some are not randomised
• Placebo-controlled trials are lacking

Therefore, the evidence is promising but insufficient to consider it a standard treatment.

CBD safety and possible side effects

Oral CBD safety

The most frequent adverse effects of oral CBD are usually mild and transient.

In some cases, alterations in liver enzymes have been detected. CBD can interact with liver enzymes (CYP450), affecting other medications (12).

Topical CBD safety on atopic skin

Topical use of CBD could involve lower systemic risk by acting mainly at a local level.

Even so, the following should be considered:

• Possible skin reactions
• Product quality and purity
• Presence or absence of THC

Quality, stability and regulation of CBD in Spain and Europe

In Europe, CBD in cosmetics is regulated under EU legislation.

Key aspects:

• CBD is lipophilic (fat-soluble) and sensitive to oxidation
• Light, temperature and oxygen affect its stability
• There are labelling problems in the market

Several studies show that a significant proportion of CBD products do not contain the declared concentration (13).

That is why, if you are looking for a CBD cream for atopic dermatitis, it is essential to check:

• Compliance with European regulations
• Absence of THC
• Certificates of analysis (CoA)

Should you use CBD cream for atopic dermatitis?

From a scientific point of view:

• There is biological plausibility
• Clinical evidence is limited but promising
• The quality of the product is decisive
• It does not replace prescribed treatments

A CBD cream for mild eczema could be considered as a complement if:

• It complies with European regulations
• It does not contain THC
• You consult a dermatologist, especially if you are using corticosteroids or immunomodulators

Frequently asked questions about CBD and atopic dermatitis

Does CBD cure atopic dermatitis?

No. Currently there is no scientific evidence demonstrating that CBD cures atopic dermatitis. It may have potential as a complement to relieve inflammation and itching, but it does not replace prescribed medical treatments.

Does CBD cream work for atopic eczema?

Some preliminary studies suggest that topical CBD may help reduce itching and inflammation in mild eczema (11). However, clinical evidence is still limited and more controlled trials are needed.

Does CBD help relieve itching (pruritus)?

CBD may modulate receptors involved in the transmission of itching (8), which explains its possible anti-itch effect. It is one of the most researched applications of CBD in atopic dermatitis.

Is it safe to use topical CBD on atopic skin?

In general, topical CBD is considered low risk when used in regulated cosmetic products in the EU. Even so, it is important to choose quality products, without THC, and with certificates of analysis.

Is CBD cream legal in Spain and Europe?

Yes, CBD is legal in cosmetics in the European Union provided it complies with current regulations and does not contain THC. It is essential to purchase products that comply with European regulations and are correctly labelled.

Conclusion

CBD for atopic dermatitis represents an emerging field in dermatology, as the available research suggests possible benefits regarding:

• Inflammation
• Itching (pruritus)
• Skin microbiota

However, randomised, placebo-controlled clinical trials are needed to confirm its efficacy.

CBD is not a miracle cure for atopic eczema, but in the future it could form part of integrated and personalised strategies for managing atopic dermatitis.

If you are considering using topical CBD for itching in atopic dermatitis, get well informed, review the product quality and consult a healthcare professional.

To learn more, we also analyse CBD for psoriasis and the benefits of CBD for acne, other common skin conditions.

This article is for informational purposes only and does not constitute medical advice. Cannactiva products are not medicines or food supplements and are sold in accordance with European regulations for external use. This information and Cannactiva products are not intended to diagnose, treat, cure or prevent any disease. If you are taking medication or have a health condition, consult a healthcare professional before using CBD.

References

1. Eberlein, B., Eicke, C., Reinhardt, H. W., & Ring, J. (2008). Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). Journal of the European Academy of Dermatology and Venereology, 22(1), 73–82. https://doi.org/10.1111/j.1468-3083.2007.02351.x
2. He, M., Shi, J., Wu, C., Xu, Y. J., & Liu, Y. (2024). Integrating Lipidomics, Metabolomics, and Network Pharmacology to Reveal the Mechanism of Cannabidiol against Inflammation in High-Fat, High-Cholesterol Diet-Induced Mice. Journal of Agricultural and Food Chemistry, 72(34), 19246–19256. https://doi.org/10.1021/acs.jafc.4c04994
3. Blaskovich, M.A.T., Kavanagh, A.M., Elliott, A.G. et al. (2021). The antimicrobial potential of cannabidiol. Communications Biology, 4, 7. https://doi.org/10.1038/s42003-020-01530-y
4. Nikan, M., Nabavi, S. M., & Manayi, A. (2016). Ligands for cannabinoid receptors, promising anticancer agents. Life Sciences, 146, 124–130. https://doi.org/10.1016/j.lfs.2015.12.053
5. Eagleston, L. R., Kalani, N. K., Patel, R. R., Flaten, H. K., Dunnick, C. A., & Dellavalle, R. P. (2018). Cannabinoids in dermatology: a scoping review. Dermatology Online Journal, 24(6). https://escholarship.org/uc/item/7pn8c0sb
6. Mujahid, K., Rasheed, M.S., Sabir, A. et al. (2025). Cannabidiol as an immune modulator: A comprehensive review. Saudi Pharmaceutical Journal, 33, 11. https://doi.org/10.1007/s44446-025-00005-7
7. Atalay Ekiner, S., Gęgotek, A., & Skrzydlewska, E. (2022). The molecular activity of cannabidiol in the regulation of Nrf2 system interacting with NF-κB pathway under oxidative stress. Redox Biology, 57, 102489. https://doi.org/10.1016/j.redox.2022.102489
8. Chaoul, N., Palazzo, S., Cinquantasei, A., Aresta, V., De Chirico, C., & Albanesi, M. (2024). Cannabidiol modulation of immune cell function: in vitro insights and therapeutic implications for atopic dermatitis. Postępy Dermatologii i Alergologii, 41(4), 408–414. https://doi.org/10.5114/ada.2024.142182
9. Sivesind, T. E., Maghfour, J., Rietcheck, H., Kamel, K., Malik, A. S., & Dellavalle, R. P. (2022). Cannabinoids for the Treatment of Dermatologic Conditions. JID Innovations, 2(2), 100095. https://doi.org/10.1016/j.xjidi.2022.100095
10. Callaway, J., Schwab, U., Harvima, I., Halonen, P., Mykkänen, O., Hyvönen, P., & Järvinen, T. (2005). Efficacy of dietary hempseed oil in patients with atopic dermatitis. Journal of Dermatological Treatment, 16(2), 87–94. https://doi.org/10.1080/09546630510035832
11. Makhakhe, L. (2022). Topical cannabidiol (CBD) in skin pathology - A comprehensive review and prospects for new therapeutic opportunities. South African Family Practice, 64(1), e1–e4. https://doi.org/10.4102/safp.v64i1.5493
12. Eadie, L., Lo, L. A., Boivin, M., Deol, J. K., & MacCallum, C. A. (2024). Clinical guidance for cannabidiol-associated hepatotoxicity: A narrative review. Journal of Gastroenterology and Hepatology, 39(12), 2522–2532. https://doi.org/10.1111/jgh.16730
13. Bizarro, A. F., Schmidt, V. M., Fernandes, B., Pinto, M., Pereira, H., Marto, J., & Lourenço, A. M. (2025). The Potential of Cannabidiol for Treating Canine Atopic Dermatitis. Veterinary Sciences, 12(2), 159. https://doi.org/10.3390/vetsci12020159